Next Article in Journal
Oxidative Stress in Neurodegenerative Diseases: From Preclinical Studies to Clinical Applications
Previous Article in Journal
Diagnostic Criteria for Fibromyalgia: Critical Review and Future Perspectives
Previous Article in Special Issue
Chronic Kidney Disease: The Silent Epidemy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 9
Issue 4
10.3390/jcm9041224
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to J. Clin. Med. 2019, 8(7), 1066.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066

by
Domenico Russo
1,*,
Rocco Tripepi
2,
Fabio Malberti
3,
Biagio Di Iorio
4,
Bernadette Scognamiglio
1,
Luca Di Lullo
5,
Immacolata Gaia Paduano
1,
Giovanni Luigi Tripepi
2 and
Vincenzo Antonio Panuccio
6
1
Department of Public Health, University of Naples FEDERICO II, 80131 Naples, Italy
2
Institute of Clinical Physiology (IFC-CNR) Research Unit of Reggio Calabria, 89124 Reggio Calabria, Italy
3
Department of Nephrology Cremona Hospital, 26100 Cremona, Italy
4
Department of Nephrology AORN Cardarelli, 80131 Naples, Italy
5
Department of Nephrology Ospedale “Parodi Delfino” di Colleferro (Roma), Colleferro, 00034 Roma, Italy
6
Nephrology, Dialysis and transplantation Unit G.O.M. “Bianchi Melacrino Morelli”, 89121 Reggio Calabria, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(4), 1224; https://doi.org/10.3390/jcm9041224
Submission received: 25 February 2020 / Accepted: 26 February 2020 / Published: 24 April 2020
(This article belongs to the Special Issue Clinical Symptoms, Diagnostics and Treatments of Chronic Kidney Diseases (CKD))
Browse Figures
Versions Notes
The authors wish to make the following corrections to the previous publication [1] in the text, Table 1 and Table 2, and also Figure 1.
In the text on page 2, it is reported that “The following levels of serum calcium were used for the definition of hypocalcemia: < 7.0 mEq/L; ≥ 7.0 but ≤ 7.5 mEq/L; ≥ 7.5 but < 8.3 mEq/L”.
This statement needs to be corrected: “The following levels of serum calcium were used for the definition of hypocalcemia: < 7.0 mg/dL; ≥ 7.0 but ≤ 7.5 mg/dL; > 7.5 but < 8.3 mg/dL”.
We wish to correct the caption of Table 1 where serum calcium concentrations are reported as mEq/L instead of mg/dL.
The caption of the amended Table 1 is:
We wish to correct the caption of Table 2 where serum calcium concentrations are reported as mEq/L instead of mg/dL and etelcalcetide is reported as Parsabiv (trade name).
The caption of the amended Table 2 is:
We wish to correct the caption of Figure 1 where serum calcium concentrations are reported as mEq/L instead of mg/dL.
The caption of the amended Figure 1 is:
The authors apologize to the readers for any inconvenience caused by these changes. It is important to state that this correction does not affect our study’s results and involves no changes or modifications in the original data supporting our results. The original manuscript [1] will remain online on the article webpage, with reference to this Correction.

Conflicts of Interest

The authors declare no conflict of interest.

Reference

  1. Russo, D.; Tripepi, R.; Malberti, F.; di Iorio, B.; Scognamiglio, B.; di Lullo, L.; Paduano, I.G.; Tripepi, G.L.; Panuccio, V.A. Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Jcm 09 01224 g001 550
Figure 1. P for the trend of intact parathyroid hormone (iPTH) (panel a), serum calcium (panel b), serum phosphate (panel c), alkaline phosphatase (panel d) over time was obtained using linear regression models weighted for patients’ identification (see methods for more details).
Figure 1. P for the trend of intact parathyroid hormone (iPTH) (panel a), serum calcium (panel b), serum phosphate (panel c), alkaline phosphatase (panel d) over time was obtained using linear regression models weighted for patients’ identification (see methods for more details).
Jcm 09 01224 g001
Jcm 09 01224 g002 550
Figure 1. P for the trend of intact parathyroid hormone (iPTH) (panel a), serum calcium (panel b), serum phosphate (panel c), alkaline phosphatase (panel d) over time was obtained using linear regression models weighted for patients’ identification (see methods for more details).
Figure 1. P for the trend of intact parathyroid hormone (iPTH) (panel a), serum calcium (panel b), serum phosphate (panel c), alkaline phosphatase (panel d) over time was obtained using linear regression models weighted for patients’ identification (see methods for more details).
Jcm 09 01224 g002
Table
Table 1. Patients’ Characteristics.
Table 1. Patients’ Characteristics.
Total Group
(n = 168)		Naïve Group
(n = 56)		Switch Group
(n = 112)		p
(Naïve vs Switch)
Age (years)61 ± 1464 ± 1459 ± 140.04
Male (%)5752600.32
Dialysis vintage (month)58 (IQR 32–102)35 (IQR 14–63)69 (IQR 48–120)<0.001
Diabetes (%)2531220.23
Cardiovascular comorbidities (%)7370750.53
iPTH (pg/mL)636 (IQR 493–916)602 (IQR 509–800)664 (IQR 495–947)0.67
Serum Calcium (mEq/L)9.0 ± 1.09.1 ± 0.79.0 ± 1.10.60
Serum Phosphate (mg/dL)5.6 ± 1.45.5 ± 1.45.6 ± 1.40.83
Alkaline Phosphate (U.I./L)131 (IQR 83–201)111 (IQR 74–159)148 (IQR 88–221)0.02
Hb (gr/dL)11.1 ± 1.411.0 ± 1.211.1 ± 1.40.58
ESA treatment (%)8788870.97
Phosphate binders therapy (%)9693970.17
Calcium containing binders (%)1825140.09
Vitamin D therapy (%)7583710.09
Native Vitamin D therapy (%)5460.59
Previous cinacalcet treatment (%)670100N/A
IQR, interquartile range; iPTH, intact parathyroid hormone; Hb, hemoglobin; ESA, erythropoietin-stimulating agent.
Table
Table 1. Patients’ Characteristics.
Table 1. Patients’ Characteristics.
Total Group
(n = 168)		Naïve Group
(n = 56)		Switch Group
(n = 112)		p
(Naïve vs Switch)
Age (years)61 ± 1464 ± 1459 ± 140.04
Male (%)5752600.32
Dialysis vintage (month)58 (IQR 32–102)35 (IQR 14–63)69 (IQR 48–120)<0.001
Diabetes (%)2531220.23
Cardiovascular comorbidities (%)7370750.53
iPTH (pg/mL)636 (IQR 493–916)602 (IQR 509–800)664 (IQR 495–947)0.67
Serum Calcium (mg/dL)9.0 ± 1.09.1 ± 0.79.0 ± 1.10.60
Serum Phosphate (mg/dL)5.6 ± 1.45.5 ± 1.45.6 ± 1.40.83
Alkaline Phosphate (U.I./L)131 (IQR 83–201)111 (IQR 74–159)148 (IQR 88–221)0.02
Hb (gr/dL)11.1 ± 1.411.0 ± 1.211.1 ± 1.40.58
ESA treatment (%)8788870.97
Phosphate binders therapy (%)9693970.17
Calcium containing binders (%)1825140.09
Vitamin D therapy (%)7583710.09
Native Vitamin D therapy (%)5460.59
Previous cinacalcet treatment (%)670100N/A
IQR, interquartile range; iPTH, intact parathyroid hormone; Hb, hemoglobin; ESA, erythropoietin-stimulating agent.
Table
Table 2. Cases of hypocalcemia.
Table 2. Cases of hypocalcemia.
Days after Parsabiv<7.0 mEq/L≥7.0 or <7.5 mEq/L≥7.5 or <8.3 mEq/L
303/168 (1.8%)025/168 (14.9%))
601/129 (0.8%)7/129 (5.4%)28/129 (21.7%)
902/111 (1.8%)2/111 (1.8%)27/111 (24.3%)
1201/80 (1.3%)1/80 (1.3%)21/80 (26.2%)
1501/61 (1.6%)6/61 (9.8%)11/61 (18.0%)
18001/44 (2.3%)11/44 (25.0%)
21001/51 (2.0%)15/51 (29.4%)
Table
Table 2. Cases of hypocalcemia.
Table 2. Cases of hypocalcemia.
Days after Etelcalcetide<7.0 mg/dL≥7.0 or ≤7.5 mg/dL>7.5 or <8.3 mg/dL
303/168 (1.8%)025/168 (14.9%))
601/129 (0.8%)7/129 (5.4%)28/129 (21.7%)
902/111 (1.8%)2/111 (1.8%)27/111 (24.3%)
1201/80 (1.3%)1/80 (1.3%)21/80 (26.2%)
1501/61 (1.6%)6/61 (9.8%)11/61 (18.0%)
18001/44 (2.3%)11/44 (25.0%)
21001/51 (2.0%)15/51 (29.4%)

Share and Cite

MDPI and ACS Style

Russo, D.; Tripepi, R.; Malberti, F.; Di Iorio, B.; Scognamiglio, B.; Di Lullo, L.; Paduano, I.G.; Tripepi, G.L.; Panuccio, V.A. Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066. J. Clin. Med. 2020, 9, 1224. https://doi.org/10.3390/jcm9041224

AMA Style

Russo D, Tripepi R, Malberti F, Di Iorio B, Scognamiglio B, Di Lullo L, Paduano IG, Tripepi GL, Panuccio VA. Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066. Journal of Clinical Medicine. 2020; 9(4):1224. https://doi.org/10.3390/jcm9041224

Chicago/Turabian Style

Russo, Domenico, Rocco Tripepi, Fabio Malberti, Biagio Di Iorio, Bernadette Scognamiglio, Luca Di Lullo, Immacolata Gaia Paduano, Giovanni Luigi Tripepi, and Vincenzo Antonio Panuccio. 2020. "Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066" Journal of Clinical Medicine 9, no. 4: 1224. https://doi.org/10.3390/jcm9041224

APA Style

Russo, D., Tripepi, R., Malberti, F., Di Iorio, B., Scognamiglio, B., Di Lullo, L., Paduano, I. G., Tripepi, G. L., & Panuccio, V. A. (2020). Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066. Journal of Clinical Medicine, 9(4), 1224. https://doi.org/10.3390/jcm9041224

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop